MiniMed™ 780G System: Improving Clinical Outcomes while Reducing Diabetes Management Burden - Industry Symposium Supported by Medtronic International Trading Sàrl

Session description - Innovation of technology in type 1 diabetes has transformed the therapy and significantly improved both clinical and patient related outcomes. In this symposium, the most recent data on the transformation brought by the introduction of automated insulin delivery system - the MiniMed™ 780G system-, on goals obtainment in real world will be presented. The opportunities brought by these to onboard a wider population of people with diabetes, even those without extensive exposure to technology, will be demonstrated. Further innovation toward extending infusion sets wear to 7 days, and its performance with automated insulin delivery system will be presented, as an additional step toward improving users’ experience. A look toward the future innovation will be offered by the leaders of Medtronic R&D